AbbVie (ABBV)
$173.15
0.00 (0.00%)
ABBV Stock Quote Delayed 30 Minutes
52 Biotechnology Stocks to Sell Now
The overall ratings of 52 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
32
Day's Range
-
52-Week Range
$135.85 - $182.89
Dividend & Yield
$5.92 (3.42%)
ABBV Stock Predictions, Articles, and AbbVie News
Without Drugs, Johnson & Johnson Has Nothing (JNJ)
Johnson & Johnson (JNJ) showed investors its smallest earnings beat in nearly a year. The upside: The dividend on JNJ stock is well-covered.
Gilead Sciences, Inc. Is More Than an HCV Play (GILD)
Gilead Sciences (GILD) stock is a bargain at these prices. Traders just have yet to see the glass as half full.
24 Biotechnology Stocks to Buy Now
24 Biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an "A" ("strong buy") or "B" overall ("buy").
FDA Issues Warning on Hepatitis C Drugs
The Food and Drug Administration (FDA) has issued a warning surrounding several Hepatitis C drugs such as Sovaldi, Harvoni and Gilead Sciences.
25 Biotechnology Stocks to Buy Now
25 Biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an "A" ("strong buy") or "B" overall ("buy").
A “Don’t Blink” Opportunity In Regeneron Pharmaceuticals Inc (REGN)
Strong growth prospects and a constructive chart in REGN stock support a bullish spread in Regeneron.
AbbVie Inc (ABBV) Has More Blockbusters on the Horizon
AbbVie (ABBV) isn't just resting on the success of Humira; this major pharmaceutical firm is building for a long, strong future.
3 Big Chart Stocks for Friday: Oracle Corporation (ORCL), salesforce.com, inc. (CRM) and AbbVie Inc (ABBV)
Salesforce (CRM), AbbVie (ABBV) and Oracle (ORCL) have all increased in volatility selling this week, as have broken key technical support.
3 Big Stock Charts: Netflix, Inc (NFLX), Intel Corporation (INTC) and Abbvie Inc (ABBV)
Intel's (INTC) quiet rally has it prepared to accelerate to new multiyear highs, but AbbVie (ABBV) and Netflix (NFLX) could be headed lower.
There’s More to Johnson & Johnson (JNJ) Than Meets the Eye
Johnson & Johnson (JNJ) has an impressive pipeline most investors don't fully appreciate. This isn't your father's stock.
3 Big Stock Charts for Wednesday: Cisco Systems, Inc. (CSCO), Baidu Inc (ADR) (BIDU) and AbbVie Inc (ABBV)
The time to identify a wish list of stocks to buy on a pullback is now. Keep watch on Cisco Systems (CSCO), Baidu (BIDU) and AbbVie (ABBV).
Trade of the Day: ABBV Stock on the Verge of a Major Breakout
AbbVie Inc is challenging the recent double-top above $65.
3 Big Stock Charts for Tuesday: AbbVie Inc (ABBV), Gilead Sciences, Inc. (GILD) and Sprint Corp (S)
AbbVie (ABBV), Gilead (GILD) and Sprint (S) are all moving today after their respective earnings reports. All three have additional profit potential for those queued into these technical pictures.
